Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics
- PMID: 33530812
- DOI: 10.1080/02652048.2021.1876175
Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics
Abstract
Aim: Nano drug delivery systems can provide the opportunity to reduce side effects and improve the therapeutic aspect of a variety of drugs. Bortezomib (BTZ) is a proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma. Severe side effects of BTZ are the major dose-limiting factor. Particulate drug delivery systems for BTZ are polymeric and lipidic drug delivery systems. This review focussed on lipidic-nano drug delivery systems (LNDDSs) for the delivery of BTZ.
Results: LNDDSs including liposomes, solid lipid nanoparticles, and self-nanoemulsifying drug delivery systems showed reduce systemic side effects, improved therapeutic efficacy, and increased intestinal absorption. Besides LNDDSs were used to target-delivery of BTZ to cancer.
Conclusion: Overall, LNDDSs can be considered as a novel delivery system for BTZ to resolve the treatment-associated restrictions.
Keywords: Bortezomib; formulation; liposomes; pharmacokinetics; self-nanoemulsifying drug delivery systems; solid lipid nanoparticles.
Similar articles
-
Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.Anticancer Agents Med Chem. 2020;20(6):643-650. doi: 10.2174/1871520620666200127141328. Anticancer Agents Med Chem. 2020. PMID: 31985384 Review.
-
The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.Anticancer Agents Med Chem. 2020;20(6):700-708. doi: 10.2174/1871520620666200101150640. Anticancer Agents Med Chem. 2020. PMID: 31893998
-
Enhancement of the intestinal absorption of bortezomib by self-nanoemulsifying drug delivery system.Pharm Dev Technol. 2020 Mar;25(3):351-358. doi: 10.1080/10837450.2019.1699109. Epub 2019 Dec 11. Pharm Dev Technol. 2020. PMID: 31810410
-
Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.J Control Release. 2015 Aug 10;211:44-52. doi: 10.1016/j.jconrel.2015.05.286. Epub 2015 May 29. J Control Release. 2015. PMID: 26031842
-
The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.Expert Opin Drug Discov. 2017 Feb;12(2):225-235. doi: 10.1080/17460441.2017.1268596. Epub 2016 Dec 20. Expert Opin Drug Discov. 2017. PMID: 27917682 Free PMC article. Review.
Cited by
-
Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies.Pharmaceuticals (Basel). 2023 Jan 12;16(1):111. doi: 10.3390/ph16010111. Pharmaceuticals (Basel). 2023. PMID: 36678608 Free PMC article. Review.
-
In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases.Eur J Pharmacol. 2022 Oct 15;932:175192. doi: 10.1016/j.ejphar.2022.175192. Epub 2022 Aug 16. Eur J Pharmacol. 2022. PMID: 35981605 Free PMC article. Review.
-
Big Data Analysis of Manufacturing and Preclinical Studies of Nanodrug-Targeted Delivery Systems: A Literature Review.Biomed Res Int. 2022 Jul 30;2022:1231446. doi: 10.1155/2022/1231446. eCollection 2022. Biomed Res Int. 2022. Retraction in: Biomed Res Int. 2023 Jun 21;2023:9759424. doi: 10.1155/2023/9759424. PMID: 35941977 Free PMC article. Retracted. Review.
-
Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma.Mini Rev Med Chem. 2024;24(9):895-907. doi: 10.2174/1389557523666230915103121. Mini Rev Med Chem. 2024. PMID: 37724679 Review.
-
Identification of PSMD7 as a prognostic factor correlated with immune infiltration in head and neck squamous cell carcinoma.Biosci Rep. 2021 Mar 26;41(3):BSR20203829. doi: 10.1042/BSR20203829. Biosci Rep. 2021. PMID: 33687056 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
